Pfizer (NYSE:PFE) Price Target Raised to $35.00

Pfizer (NYSE:PFE) had its target price hoisted by Scotiabank from $33.00 to $35.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a sector outperform rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the company. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Citigroup lifted their price objective on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday. HSBC boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Six equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $30.39.

Pfizer Stock Down 1.7%

NYSE PFE traded down $0.50 during mid-day trading on Wednesday, reaching $29.38. The stock had a trading volume of 48,291,518 shares, compared to its average volume of 30,697,644. Pfizer has a 1 year low of $23.62 and a 1 year high of $31.44. The stock has a market cap of $167.46 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. The company has a fifty day moving average price of $28.74 and a 200 day moving average price of $26.90. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $16.58 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the prior year, the firm posted $0.87 EPS. The firm’s quarterly revenue was down .4% on a year-over-year basis. On average, research analysts expect that Pfizer will post 3.03 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. Pfizer’s payout ratio is 245.71%.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of the business. TOWER TRUST & INVESTMENT Co raised its stake in Pfizer by 1.9% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after purchasing an additional 357 shares during the period. Angeles Wealth Management LLC lifted its holdings in Pfizer by 2.2% in the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 358 shares in the last quarter. Manchester Financial Inc. boosted its stake in Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 365 shares during the period. Signature Equity Partners LLC boosted its stake in Pfizer by 22.9% in the 3rd quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 385 shares during the period. Finally, Delta Financial Advisors LLC grew its holdings in Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

About Pfizer